|
|
|
|
| The 5th In Vivo Cell Engineering & Gene Editing Summit brings together leading scientists, biopharma innovators, and industry strategists to advance the next generation of in vivo delivery and editing technologies. With growing momentum behind extrahepatic targeting, early clinical readouts, and scalable manufacturing, this meeting offers critical insights to accelerate IND‑enabling work and shape the future of accessible, durable in vivo therapies. |
|
|
|
|
By Advancing RNA Live | Though there are a lot of exciting advancements with novel lipid chemistries, CMC Consultant Sujit Jain provides an important reality check for us: These innovations break established platforms, requiring fresh process development, complex impurity profiling, and new vendor qualifications. | |
|
|
|
The Potency Chains Of Events For mRNA/LNP Therapeutics | By Steve Wolk, Ph.D., Sinawali Biotechnology Solutions | Potency in mRNA/LNP therapies depends on two chains: manufacturing/cold chain integrity and complex in vivo delivery. Breakdowns at any step — from stability to translation — can limit efficacy and safety. |
|
|
Inside Alnylam's Playbook For High Volume siRNA Production | By Anna Rose Welch, Advancing RNA | In this installment, Maines and Nechev outline what they’ve learned thus far about the science of enzymatic ligation, while also paying credence to the unknowns and existing barriers that, as a frontrunner, Alnylam will inevitably (but willingly) be tasked with facing in the future. |
|
|
|
|
| Manufacturing Strategies For mRNA Vaccines And Therapeutics | White Paper | By Laurens Vergauwen, Dr. Nargisse El Hajjami, et al., MilliporeSigma | mRNA has emerged as a promising modality offering a great deal of versatility for a wide range of therapeutics and vaccines with its use of non-viral delivery systems. |
|
|
|
| Screening T7 Polymerases To Optimize xRNA Yield And Quality | Article | By Jing Zhu, Ph.D., Recipharm Advanced Bio | Discover how the evolution of T7 polymerase is optimizing in vitro transcription for RNA therapeutics. Learn to balance performance, cost, and supply to make smart choices for your xRNA manufacturing. |
|
|
|
|
|
|
.png){kind=logo}
